Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Dec:208:35-38.
doi: 10.1016/j.thromres.2021.10.006. Epub 2021 Oct 15.

Pre-admission anticoagulant therapy and mortality in hospitalized COVID-19 patients: A retrospective cohort study

Thijs F van Haaps  1 , Didier Collard  2 , Frits H M van Osch  3 , Saskia Middeldorp  4 , Michiel Coppens  2 , Martijn D de Kruif  5 , Eline A Vlot  6 , Renée A Douma  7 , Hugo Ten Cate  8 , Nicole P Juffermans  9 , Niels Gritters  10 , Alexander P Vlaar  11 , Auke C Reidinga  12 , Marjolein A Heuvelmans  13 , Matthijs Oudkerk  13 , Harry R Büller  2 , Joop P W van den Bergh  14 , Arno Maas  14 , Marije Ten Wolde  7 , Suat Simsek  15 ; Corona Research Fund Amsterdam UMC; Martijn Beudel  16 , Nick van Es  2 ; Dutch COVID & Thrombosis Coalition
Affiliations
Comment

Pre-admission anticoagulant therapy and mortality in hospitalized COVID-19 patients: A retrospective cohort study

Thijs F van Haaps et al. Thromb Res. 2021 Dec.
No abstract available

Keywords: Anticoagulants; COVID-19; Mortality; SARS-CoV-2; Thrombosis.

PubMed Disclaimer

Conflict of interest statement

TFH, DC, FHMvO, SM, MDdK, EAV, RAD, NPJ, NG, APV, ACR, MAH, MO, HRB, AM, MtW, SS, and MB have nothing to report.

MC received research support and consultancy fees from Bayer and consultancy fees from Daiichi Sankyo, outside the submitted work. All fund were transferred to his institute.

HtC reports receiving advisory board honoraria from LEO Pharma, Portola/Alexion, Antheos and Pfizer; research support from Bayer and Pfizer; consultancy fees from Alveron; all reimbursements were transferred to CARIM.

JPWvdB received research support and advisory board honoraria from Amgen and UCB which were transferred to his institute.

NvE reports receiving advisory board honoraria from LEO Pharma, Daiichi-Sankyo, and Pfizer which were transferred to his institute.

CovidPredict is funded by Corona Research Fund, Amsterdam UMC, and Dr. C.J. Vaillant Fund, all to D. van de Beek. Furthermore, the analysis was made possible by an unrestricted grant from Daiichi-Sankyo.

The Dutch COVID & Thrombosis Coalition (DCTC) is supported by grants from ZON-MW and the Dutch Thrombosis Foundation, project number: 10430012010004.

Other authors have nothing to report.

Figures

Fig. 1
Fig. 1
All-cause mortality (A–B) and ICU admission (C–D) in patients with and without anticoagulant therapy. Time from hospital admission to death and ICU admission overall (A and C) and in the matched groups (B and D).
See this image and copyright information in PMC

Comment on

  • Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.
    REMAP-CAP Investigators; ACTIV-4a Investigators; ATTACC Investigators; Goligher EC, Bradbury CA, McVerry BJ, Lawler PR, Berger JS, Gong MN, Carrier M, Reynolds HR, Kumar A, Turgeon AF, Kornblith LZ, Kahn SR, Marshall JC, Kim KS, Houston BL, Derde LPG, Cushman M, Tritschler T, Angus DC, Godoy LC, McQuilten Z, Kirwan BA, Farkouh ME, Brooks MM, Lewis RJ, Berry LR, Lorenzi E, Gordon AC, Ahuja T, Al-Beidh F, Annane D, Arabi YM, Aryal D, Baumann Kreuziger L, Beane A, Bhimani Z, Bihari S, Billett HH, Bond L, Bonten M, Brunkhorst F, Buxton M, Buzgau A, Castellucci LA, Chekuri S, Chen JT, Cheng AC, Chkhikvadze T, Coiffard B, Contreras A, Costantini TW, de Brouwer S, Detry MA, Duggal A, Džavík V, Effron MB, Eng HF, Escobedo J, Estcourt LJ, Everett BM, Fergusson DA, Fitzgerald M, Fowler RA, Froess JD, Fu Z, Galanaud JP, Galen BT, Gandotra S, Girard TD, Goodman AL, Goossens H, Green C, Greenstein YY, Gross PL, Haniffa R, Hegde SM, Hendrickson CM, Higgins AM, Hindenburg AA, Hope AA, Horowitz JM, Horvat CM, Huang DT, Hudock K, Hunt BJ, Husain M, Hyzy RC, Jacobson JR, Jayakumar D, Keller NM, Khan A, Kim Y, Kindzelski A, King AJ, Knudson MM, Kornblith AE, Kutcher ME, Laffan MA, Lamontagne F, Le G… See abstract for full author list ➔ REMAP-CAP Investigators, et al. N Engl J Med. 2021 Aug 26;385(9):777-789. doi: 10.1056/NEJMoa2103417. Epub 2021 Aug 4. N Engl J Med. 2021. PMID: 34351722 Free PMC article. Clinical Trial.

References

    1. Nopp S., et al. Risk of venous thromboembolism in patients with COVID-19: a systematic review and meta-analysis. 2020;4(7):1178–1191. - PMC - PubMed
    1. WHO COVID-19 Clinical management: living guidance. https://wwwwhoint/publications/i/item/WHO-2019-nCoV-clinical-2021-1
    1. RESEARCHERS C.P. 2020. https://covidpredict.org/en
    1. Tremblay D., et al. Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study. Blood. 2020;136(1):144–147. - PMC - PubMed
    1. Paranjpe I., et al. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J. Am. Coll. Cardiol. 2020;76(1):122–124. - PMC - PubMed